BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 10, 2026
Home » Blogs » BioWorld MedTech Perspectives » Canada knows innovation

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Canada knows innovation

Nov. 21, 2011
By Amanda Pedersen

Flag of Ontario

Hockey isn’t the only thing our northern neighbors do well. Canada – Ontario in particular – knows innovation.

While the U.S. has struggled in recent years to find ways to maintain its leadership position in medical innovation – Ontario has its own strategy that seems to be working out quite well for the Canadian province. More than $13.9 billion in industrial and university-based R&D is performed in Ontario every year.

So, what’s their secret? Ontario offers all the key ingredients for attracting life sciences companies: the right people, the right cost, and a healthy research environment.

Let’s start with the people part of the equation. Ontario has more than 100,000 researchers in its talent pool. Thousands of young researchers and technicians graduate from the province’s 44 universities and colleges every year. Ontario attracts top scientists from around the world with generous funding programs, top-notch lab facilities and the opportunity to work on leading-edge projects in a collaborative environment.

The next ingredient – cost – is particularly impressive, given the troubles U.S. medical device companies are facing with the recent medical device tax. Canada’s R&D tax incentive program is one of the most generous in the world. The after-tax cost of $100 R&D expenditure can be reduced to roughly $56 or even less than $37 for small businesses. A survey of international business costs last year showed that Canada offers the lowest R&D costs among the G7. That same survey reported that the country’s overall business costs were the lowest in the G7 for R&D intensive sectors – including medical devices.

Finally, Ontario encourages business and economic growth by creating the right environment for innovation. The province has partnered with the private sector to invest nearly $3 billion over an eight-year period to support research and commercialization at its universities, hospitals and research institutes. In addition to the generous federal R&D tax program mentioned above, Ontario tops that up with additional tax incentives such as its Ontario Research and Development Tax Credit, the Ontario Innovation Tax Credit, and the Ontario Business-Research Institute tax credit.

As part of the media tour I’ll be participating in today, organized by the Ontario Ministry of Economic Development and Innovation, I will be getting a first-hand look at some of the incredible medical technology being developed here. Check back tomorrow to find out how it went!

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 10, 2026.
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing